|Publication number||US2801201 A|
|Publication date||30 Jul 1957|
|Filing date||9 Apr 1953|
|Priority date||9 Apr 1953|
|Publication number||US 2801201 A, US 2801201A, US-A-2801201, US2801201 A, US2801201A|
|Original Assignee||Lincoln Lab Inc|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Referenced by (26), Classifications (13)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent BURN TREATMENT FILLING FOR PRESSURE PACKAGED DISPENSER Frank Kipnis, Decatur, I11., assignor to Lincoln Laboratories, Inc., Decatur, I11., a corporation of Indiana No Drawing. Application April 9, 1953, Serial No. 347,851
2 Claims. (Cl. 167-58) practically every case is an emergency requiring immediate treatment which has to be followed up in the physicians ofiice or hospital by more extensive treatment. Suitable preparations for the emergency treatment of burns should therefore be immediately usable in such a way as to provide a'protective coating over the burn area inhibiting bacterial invasion and also provide immediate relief from pain. It is also a desirable requirement of a formulation for the treatment of burns that it be useful both as an emergency treatment preparation and also by the physician for subsequent care of the burn area.
The present invention is directed to a formulation which not only fulfills the requirements of a preparation for the emergency treatment of burns but also is fully satisfactory and effective for the continuing treatment of burns during all stages of therapy.
A particularly desirable feature of my formulations is that they are adapted to be dispensed by a propellant from pressure packaged dispensers.
The satisfactory treatment of burns has been a problem of the medical profession which has long gone unsolved. That this is the case is borne out by the fact that even at this late date there is no universal agreement by the profession as to the superiorityof any one particular burn treatment. Within the space of only a few years there have been a number of burn treatment techniques which have enjoyed short periods of favor and prominence only to be discarded when more extended experience brought out their various defects. Thus, the escharotic agents such as tannic acid and silver nitrate went through a short period of popularity but are little used today because of their tendency to cause infection under the eschar, and marked scarring and contracture deformities often resulted. The use of protective coatings of petrolatum with padded pressure dressings has been in and out of favor several times and is now regarded as one of the accepted methods of burn treatment by the profession.
Still another technique or method of treatment is the so-called open or exposed treatment involving the use of adequate doses of morphine to control pain and the administration of adequate intravenous plasma.
The foregoing shows the lack of any substantial progress in the treatment of burns even though practically all other phases of medicine have advanced with steady to even dramatic strides. The problem of a satisfactory burn treatment is even more critical at this time because experience has shown that burns account for one of the largest percentages of cases requiring medical attention as the result of atomic bomb explosions. In addition, the increasing use in warfare of flame throwers and incendiary bombs has greatly increased and magnified the 2,801,201 7 Patented July 30, 1957 ice problems of burn treatment for the medical services of the armed forces.
There are several requirements which burn treatment formulation must meet in order to be wholly acceptable. It must be conveniently and speedily applied without handling the wound, it must cover smoothly and completely, it must have a topical anesthetic action, it should be bacteriostatic, bactericidal and fungicidal,-it must be easily removed when necessary, and it should minimize as much as possible the need for further treatment. The formulations comprehended by the present invention have been successfully tested clinically under a sufficiently wide variety of conditions and on a sufliciently wide number of cases so as to show that it satisfactorily meets all of the foregoing requirements.
The object of the present invention is an improved formulation for the treatment of burns which satisfactorily meets and exhibits all of the requirements which are necessary and desirable'for a satisfactory burn treatment composition and which is particularly suitable for being dispensed from pressure packaged dispensers so that it may be quickly and safely used even by the inexperienced and eliminates physical handling and contact of the wound or burn thereby minimizing pain and the possibility of infection.
Certain more specific objects of the invention will, in part, be obvious and will, in part, appear hereinafter.
For a more complete understanding of the nature and scope of the invention, reference may now be had to the following detailed description thereof wherein a presently preferred embodiment thereof is set forth in detail and a number of modifications therein are suggested which fall within the scope of the invention.
Example 1 A solution is prepared having the following formulation: Grams Tyrothricin l p-Chloro-m-xylenol 20 Hyamine 1622 (para diisobutyl-phenoxyethoxyethyl dimethyl benzyl ammonium chloride monohydrate) 2 Ethyl p-aminobenzoate 4O Polyethylene glycol 400, q. s 2250 77 grams of the foregoing solution and 8 grams of a paste consisting of hexadienol (also referred to as hexenol or hexadenol), which is a mixture of tetracosanes and oxidation products thereof, are introduced into a pressure packaged dispenser of known type along with grams or more of a suitable propellant such as a mixture of 35 parts of Freon-11 (trichloromonofluoromethane) and 65 parts of Freon-12 (dichlorodifiuoromethane) or similar propellants either alone or as mixtures. The pressure pack is capped with a suitable valve' The present invention is not concerned with the details of construction of the pressure packaged dispenser itself. There are a number of commercial makes of such dispensers on the market and any one of these may be loaded with the compositions of the present invention. Suitable dispensers of this type are disclosed, for example, in Rotheim Patent No. 1,892,750, dated January 3, 1933, and in Roehr Patent No. 2,440,915, dated May 4, 1948.
The pressure packaged dispenser is a particularly advantageous device for dispersing the foregoing formulation comprising the solution and the hexadienol paste since the hexadienol does not dissolve completely in the solution and it would be difficult to handle this mixture in another way so as to obtain a comparable uniformity of dispersion. While the hexadienol paste is not completely soluble in the charge introduced into the pressure packaged dispensers, it has been found that the aerosol or col- 1 loidal mist which is dispersed from such a dispenser contains a uniform and constant ratio or proportion of the hexadienol in intimate and uniform dispersion with the solution. The pressure packaged dispenser is a particularly desirable mechanism for applying the formulation since it is always ready for instant use and is fool-proof in the sense that there is no need to handle the burn or wound directly and there is no danger of applying too much of the medicament on the wound. Accordingly, it will be seen that this formulation is especially adapted for use in emergencies since it can be applied by even the most inexperienced person without any danger of mishandling or misuse.
In addition to the therapeutic properties and benefits provided by the formulation, the application thereof in the form of an aerosol is inherently advantageous in that the'aerosol will be cooled materially due to the rapid expansion of the gases after leaving the pressure packaged dispenser resulting in a desirable cooling and pain-relieving effect at the wound or burn area.
While the formulation set forth aboveunder Example 1 is a presently preferred formulation, the proportions of the ingredients therein specified may be varied somewhat as long as they remain in approximately the same proportions and the individual components may be replaced by corresponding amounts of equivalent ingredients as follows:
Tyrothricin is an antibiotic and is useful in the foregoing formulation by reason of its solubility and stability in the particular system. It could be replaced satisfactorily with bacitracin, neomycin, terramycin and aureomycin in approximately the same amounts or concentration.
The p-chloro-m-xylenol possesses germicidal and fungicidal properties and is an excellent local antiseptic. It is essentially atoxic even by oral ingestion and it is a preferred component for this formulation. However, other local antiseptics could be used.
The Hyamine 1622 is a quaternary ammonium chloride type germicide and it can be replaced by other similar germicides such as Emulsept E607 (N lauroyl colamino formyl methyl pyridinium chloride), or Roccal (alkyl dimethyl benzyl ammonium chloride).
The ethyl p-aminobenzoate serves as a topical anaesthetic and it may be replaced by an equivalent compound such as tetracaine or butacaine.
The polyethyleneglycol 400 serves as a solvent and skin emollient and prevents the skin from cracking. It also has mild antiseptic properties. This material can be replaced by polyethyleneglycol of other molecular weights or by a mixture of different molecular weights and viscosities.
Hexadienol may be replaced by materials possessing similar properties such as the silicones (organo-silicon oxide polymers) having viscosities in the range of 50 to 200,000 centistokes.
It will be understood that the formulations may be loaded into pressure packaged dispensers of different capacities depending upon the particular requirements. Thus, the formulations may be loaded into one fluid ounce capacity dispensers for small sized first-aid kits or they may be introduced into much larger capacity dispensers for use in industrial first-aid rooms.
Having fully described my invention and illustrated embodiments thereof, what I claim as new is:
1. A burn treatment filling for a pressure packaged dispenser comprising a volatile liquid dispersant containing substantially the following formulation in parts by weight:
2. A burn treatment filling for a pressure packaged dispenser comprising a volatile liquid dispersant containing substantially the following formulation in parts by weight:
Antibiotic selected from the group consisting of tyrothricin, bacitracin, neomycin, terramycin and aureomycin 1 Local antiseptic 2O Quaternary ammonium germicide 2 Topical anaesthetic selected from the group consisting of ethyl p-aminobenzoate, tetracaine and butacaine '40 Polyethylene glycol 2250 Hexadienol 240 References Cited in the file of this patent UNITED STATES PATENTS Hamilton Sept. 6, 1949 OTHER REFERENCES I. A. M. A., Aug. 5, 1944, vol. 125, pp. 969-973, re,- print pp. 1-21, Local Treatment of Thermal Cutaneous Burns, esp. p. 15.
Lesser: Modern Burn Therapy, Drug and Cos. Ind., June 1951, pp. 732, 733, 812817'.
Choy et al.: New Local Treatment of Burns, U. S. Armed Forces Med. Joint, vol. 3, No. 9, Sept. 1952, pp. 1241-1255.
Unlisted Drugs: CTA Chlorophyll, Sept. 30, 1952, vol. 4, No. 9 page 126.
J. Am. Pharm. Assoc., Oct. 1940, Tannic Acid Jelly, page 367.
Whittet: A Review of Burn Treatment Preparations, Soap Perf. and Cos., Nov. 1944, pp. 821-823.
Vallance: Treatment of Burns, Mfg. Chemist, Oct. 1940, pages 258261.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2481419 *||13 Feb 1945||6 Sep 1949||Frederick M Turnbull||Surgical dressing|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US2975097 *||13 Nov 1957||14 Mar 1961||Modern Lab Inc||Topical analgesic composition|
|US2987439 *||7 Jan 1958||6 Jun 1961||William Cooper & Nephews Inc||Method of applying an aerosol to the eye|
|US3069320 *||18 Nov 1958||18 Dec 1962||American Cyanamid Co||Synergistic sanitizing process with neomycin and selected cationic surface active quaternary ammonium salts|
|US3079299 *||16 Nov 1959||26 Feb 1963||Gen Aerosol Corp||Self-propelling medicinal ointment composition containing polyethylene and method ofapplication|
|US3092555 *||21 Apr 1958||4 Jun 1963||Roy H Horn||Relatively collapsible aerosol foam compositions|
|US3101297 *||15 May 1961||20 Aug 1963||Sir Properties Inc||Diaper washing composition|
|US3144391 *||28 Mar 1960||11 Aug 1964||Gillette Co||Hair-setting composition|
|US3219525 *||16 Jan 1963||23 Nov 1965||Menlo Park Lab Inc||Vaginal douche solution|
|US3219533 *||29 Nov 1962||23 Nov 1965||Merck & Co Inc||Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation|
|US3274057 *||30 Oct 1963||20 Sep 1966||Merck & Co Inc||Stable hexylresorcinol compositions|
|US3317382 *||7 Dec 1962||2 May 1967||Gillette Co||Substituted 5-phenylsalicylic acid compounds for the prevention and treatment of erythema|
|US3322624 *||1 Oct 1964||30 May 1967||Arnar Stone Lab||Low temperature resistant aerosol anesthetic preparation containing benzocaine|
|US3476853 *||13 Apr 1965||4 Nov 1969||Colgate Palmolive Co||Sprayed opaque bandage composition|
|US3624224 *||22 Dec 1969||30 Nov 1971||Schering Corp||Novel first aid products|
|US3730960 *||25 Jun 1971||1 May 1973||Plough||Novel first aid products|
|US3832459 *||18 Mar 1971||27 Aug 1974||Hysan Corp||Spray disinfectant-deodorant|
|US4086331 *||17 Jun 1976||25 Apr 1978||Technion Research And Development Foundation Ltd.||Gelatin-based compositions and a method for the generation of stabilized foams therefrom|
|US4216233 *||6 Dec 1978||5 Aug 1980||Stein Karl N||Method for treatment of skin burns in mammals|
|US4241048 *||1 May 1979||23 Dec 1980||Bristol-Myers Company||Suspension composition of benzocaine|
|US4344965 *||26 Mar 1980||17 Aug 1982||Raymond Stone||Anesthetic compositions containing benzocaine|
|US4361585 *||29 Apr 1981||30 Nov 1982||Roy Edwards||Method of treatment to relieve pain in muscles or bones|
|US4921691 *||22 Aug 1985||1 May 1990||Stockel Richard F||Spray on wound dressing compositions|
|US8652443||13 Feb 2009||18 Feb 2014||Precision Dermatology, Inc.||Foamable microemulsion compositions for topical administration|
|US20050123484 *||1 Oct 2004||9 Jun 2005||Collegium Pharmaceutical, Inc.||Non-flammable topical anesthetic liquid aerosols|
|US20060188449 *||4 Oct 2004||24 Aug 2006||Jane Hirsh||Topical aerosol foams|
|US20090232743 *||13 Feb 2009||17 Sep 2009||Collegium Pharmaceutical, Inc.||Foamable Microemulsion Compositions for Topical Administration|
|U.S. Classification||424/45, 424/DIG.130, 141/20, 424/115, 514/2.9, 514/2.4|
|International Classification||A61K9/12, C09K3/30|
|Cooperative Classification||A61K9/12, C09K3/30, Y10S424/13|
|European Classification||C09K3/30, A61K9/12|